Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to determine the efficacy and safety profile of TKI258 in 3
groups of patients with metastatic HER2 negative breast cancer (BC) stratified by FGFR1 and
hormone receptor (HR) status.